Oligoclonal and Polyclonal Antibody Preparations

Handbook of Therapeutic Antibodies: Second Edition

Volumn 3-4, Issue , 2014, Pages 1289-1308

  Gupta, Rishab K ^a,b   Glassy, Mark C ^a,c,d,e  

^a Nascent Biologics Inc   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Integrated Medical Sciences Association Foundation   (United States)

^d Rajko Medenica Research Foundation   (United States)

^e Shantha West Inc   (United States)

Author keywords

Antibody cocktails; Biologic therapeutics; Combination therapy; FDA; Immunogen; Polyclonal antibodies; Recombinant

Indexed keywords

CONTROLLED DRUG DELIVERY; DIAGNOSIS; MONOCLONAL ANTIBODIES;

BIOLOGIC THERAPEUTICS; COMBINATION THERAPY; IMMUNOGEN; POLYCLONAL ANTIBODY; RECOMBINANT;

IMMUNE SYSTEM;

EID: 84940864135     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527682423.ch44     Document Type: Chapter

References (74)

1. Glassy, M.C. and Gupta, R. (2014) Technical and ethical limitations in making human monoclonal antibodies (An Overview), in Human Monoclonal Antibodies, Humana Press, pp. 9-36.
2. Glassy, M. and McKnight, M. (2005) Requirements for human antibody cocktails for oncology. Expert Opin. Biol. Ther., 5, 1333-1338.
3. Victoria, G.D. and Nussenzweig, M.C. (2012) Germinal centers. Annu. Rev. Immunol., 30, 429-457.
4. Glassy, M.C. and McKnight, M.E. (1994) Pharming the human lymph node. Expert Opin. Invest. Drugs, 3, 1057-1063.
5. Logtenberg, T. (2007) Antibody cocktails:next-generation biopharmaceuticals with improved potency. Trends Biotechnol., 25, 390-394.
6. Hudson, P.J. and Souriau, C. (2003) Engineered antibodies. Nat. Med., 9, 129-134.
7. U.S. Department of Health and Human Services (1997) Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use, www.fda.gov/downloads/BiologicsBlood_Vaccines/GuidanceComplianceRegulatory_Information/OtherRecommendationsfor_Manufacturers/UCM153182.pdf (accessed 06 December 2013).
8. Council, E. U. (2001) Directive 2001/83/EC of the European parliament and of the council of 6 November 2001 on the community code relating to medicinal products for human use. Official Journal L, 311 (28), 11.
9. Chen, Z., Moayeri, M., Crown, D., Emerson, S., Gorshkova, I., Schuck, P., Leppla, S.H., and Purcell, R.H. (2009) Novel chimpanzee/human monoclonal antibodies that neutralize anthrax lethal factor, and evidence for possible synergy with anti-protective antigen antibody. Infect. Immun., 77, 3902-3908.
10. Mazor, O., Ben-Arie, E., Mechaly, A., Rosenfeld, R., Marcus, H., and Ordentlich, A. (2010) in The Challenge of Highly Pathogenic Microorganisms (eds B. Velan, A. Shafferman, and A. Ordentlich), Springer, New York, pp. 275-285.
11. Bakker, A.B., Python, C., Kissling, C.J., Pandya, P., Marissen, W.E., Brink, M.F., Lagerwerf, F., Worst, S., van Corven, E., Kostense, S., Hartmann, K., Weverling, G.J., Uytdehaag, F., Herzog, C., Briggs, D.J., Rupprecht, C.E., Grimaldi, R., and Goudsmit, J. (2008) First administration to humans of a monoclonal antibody cocktail against rabies virus: safety, tolerability, and neutralizing activity. Vaccine, 26L, 5922-5927.
12. Glassy, M., McKnight, M., Kotlan, B., Glassy, E., and Koda, K. (2007) Cocktails of human anti-cancer antibodies show a synergistic effect in nude mouse tumor xenografts. Hum. Antibodies, 16, 87-98.
13. Both, L., Banyard, A.C., van Dolleweerd, C., Wright, E., Ma, J.K.C., and Fooks, A.R. (2013) Monoclonal antibodies for prophylactic and therapeutic use against viral infections. Vaccine, 31, 1553-1559.
14. Meng, Q., Li, M., Silberg, M.A., Conrad, F., Bettencourt, J., To, R., Huang, C., Ma, J., Meyer, K., Shimizu, R., Cao, L., Tomic, M.T., and Marks, J.D. (2012) Domain-based assays of individual antibody concentrations in an oligoclonal combination targeting a single protein. Anal. Biochem., 421, 351-361.
15. Speed BioSystems www.speed_biosystems.com/Antibodies/OligoClonal.aspx/ (accessed 06 December 2013).
16. Pedersen, M., Jacobsen, H.J., Koefoed, K., Hey, A., Pyke, C., Haurum, J.S., and Kragh, M. (2010) Sym004: a novel synergistic anti-epidermal growth factor receptor antibody mixture with superior anticancer efficacy. Cancer Res., 70, 588-597.
17. Davies, N.L., Compson, J.E., MacKenzie, B., O'Dowd, V.L., Oxbrow, A.K.F., Heads, J.T., Turner, A., Sarkar, K., Dugdale, S.L., Jairaj, M., Christodoulou, L., Knight, D.E.O., Cross, A.S., Herve, K.J.M., Tyson, K.L., Hailu, H., Doyle, C.B., Ellis, M., Kriek, M., Cox, M., Page, M.J.T., Moore, A.R., Lightwood, D.L., and Humphreys, D.P. (2013) A mixture of functionally oligoclonal humanized monoclonal antibodies that neutralize Clostridium difficile TcdA and TcdB with high levels of in vitro potency shows in vivo protection in a hamster infection model. Clin. Vaccine Immunol., 20, 377-390.
18. Armbruster, C., Stiegler, G.M., Vcelar, B.A., Jäger, W., Köller, U., Jilch, R., Ammann, C.G., Pruenster, M., Stoiber, H., and Katinger, H.W.D. (2004) Passive immunization with the anti-HIV-1 human monoclonal antibody (hMAb) 4E10 and the hMAb combination 4E10/2F5/2G12. J. Antimicrob. Chemother., 54, 915-920.
19. Sawada, H., Iwasa, S., Nishimura, O., and Kitano, K. (1995) Efficient production of anti hepatitis B virus antibodies and their neutralizing activity in chimpanzees. Appl. Microbiol. Biotechnol., 43, 445-451.
20. Prabakaran, M., Prabhu, N., He, F., Hongliang, Q., Ho, H.T., Qiang, J., Meng, T., Goutama, M., and Kwang, J. (2009) Combination therapy using chimeric monoclonal antibodies protects mice from lethal H5N1 infection and prevents formation of escape mutants. PLoS One, 4, e5672.
21. Jamnani, F.R., Rahbarizadeh, F., Shokrgozar, M.A., Ahmadvand, D., Mahboudi, F., and Sharifzadeh, Z. (2012) Targeting high affinity and epitope-distinct oligoclonal nanobodies to HER2 over-expressing tumor cells. Exp. Cell. Res., 318, 1112-1124.
22. Schenerman, M., Kozlowski, S., Webber, K., Gazzano-Santoro, H., and Mire-Sluis, A. (2004) CMC strategy forum report:analysis and structure characterization of monoclonal antibodies. BioProcess Int., 2, 42-49.
23. ElBakri, A., Nelson, P.N., and Abu-Odeh, R.O. (2010) The state of antibody therapy. Hum. Immunol., 71, 1243-1250.
24. Golden, J.W., Zaitseva, M., Kapnick, S., Fisher, R.W., Mikolajczyk, M.G., Ballantyne, J., Golding, H., and Hooper, J.W. (2011) Polyclonal antibody cocktails generated using DNA vaccine technology protect in murine models of orthopoxvirus disease. Virol. J., 8, 441.
25. Winau, F. and Winau, R. (2002) Emil von Behring and serum therapy. Microbes Infect., 4, 185-188.
26. Kabat, E.A. (1939) The molecular weigh of antibodies. J. Exp. Med., 69, 103-118.
27. Tiselius, A. and Kabat, E.A. (1939) An electrophoretic study of immune sera and purified antibody preparations. J. Exp. Med., 69, 119-131.
28. Silverstein, A.M. (2002) The clonal selection theory: what it really is and why modern challenges are misplaced. Nat. Immunol., 3, 793-796.
29. Schwartz, R.S. (2004) Paul Ehrlich's magic bullets. N. Engl. J. Med., 350, 11.
30. Forsdyke, D.R. (1995) The origins of the clonal selection theory of immunity:a case study for evaluation in science. FASEB J., 9, 164-166.
31. Nilsson, J. and Hansson, G.K. (2008) Autoimmunity in atherosclerosis: a protective response losing control? J. Internal Med., 263, 464-478.
32. Klinman, N.R. and Press, J.L. (1975) The B cell specificity repertoire: its relationship to definable subpopulations. Transplant. Rev., 24, 41-83.
33. Getzoff, E.D., Tainer, J.A., Lerner, R.A., and Geysen, H.M. (1988) The chemistry and mechanism of antibody binding to protein antigens. Adv. Immunol., 43, 1-98.
34. Varki, A. (1992) Diversity in the sialic acids. Glycobiology, 2, 25-40.
35. Vivona, S., Gardy, J.L., Ramachandran, S., Brinkman, F.S.L., Raghava, G.P.S., Flower, D.R., and Filippini, F. (2008) Computer-aided biotechnology: from immuno-informatics to reverse. Vaccinology, 26, 190-200.
36. Still, H.F. (2012) in The Laboratory Rabbits, Guinea Pigs and Other Rodents (eds M.A. Suckow, K.A. Stevens, and R.P. Wilson), Academic Press, Waltham, MA, pp. 259-274.
37. Marlies Leenaars, P.P.A., Hendriksen, C.F.M., de Leeuw, W.A., Carat, F., Delahaut, P., Fischer, R., Halder, M., Hanly, W.C., Hartinger, J., Jann Hau, J., Lindblad, E.B., Nicklas, W., Outschoorn, I.M., and Stewart-Tull, D.E.S. (1999) The production of polyclonal antibodies in laboratory animals: the report and recommendations of ECVAM workshop 35. ATLA, 27, 79-102.
38. Sela, M. (1969) Antigens and antigenicity. Naturwissenschaften, 56, 206-211.
39. Dey, A.K. and Srivastava, I.K. (2011) Novel adjuvants and delivery systems for enhancing immune responses induced by immunogens. Expert Rev. Vaccines, 10, 227-251.
40. Zhao, X., Lin, X., Liu, G., and Wang, Z. (2012) Preparation of a polyclonal antibody against immunogenic fragment of bovine intestinal peptide transporter I (bPepTI). Adv. Biosci. Biotechnol., 3, 137-142.
41. Qi, Y.H., Shan, W.C., Liu, Y.Z., Zhang, Y.J., and Wang, J.P. (2012) Production of the polyclonal antibody against Sudan 3 and immunoassay of Sudan dyes in food samples. J. Agric. Food Chem., 60, 2116-2122.
42. Lee, N.H., Lee, J.A., Park, S.Y., Song, C.S., Choi, I.S., and Lee, J.B. (2012) A review of vaccine development and research for industry animals in Korea. Clin. Exp. Vaccine Res., 1, 18-34.
43. Dragovic, S.M., Conant, S.B., Gray, J.J., Zheng, M., Samir, P., Niu, X., Moutaftsi, M., Kaer, L.V., Sette, A., Link, A.J., and Joyce, S. (2013) Sculpting MHC class II-restricted self and non-self peptidome by the class I Agprocessing machinery and its impact on Th-cell responses. Eur. J. Immunol., 43, 1-11.
44. Blankenstein, T., Coulie, P.G., Gilboa, E., and Jaffee, E.M. (2012) The determinants of tumour immunogenicity. Nat. Rev. Cancer, 12, 307-313.
45. Orson, F.M., Rossen, R.D., Shen, X., Lopez, A.Y., Wu, Y., and Kosten, T.R. (2013) Spontaneous development of IgM anti-cocaine antibodies in habitual cocaine users: effect on IgG antibody responses to a cocaine cholera toxin B conjugate vaccine. Am. J. Addict., 22, 169-174.
46. Bruder, J.T., Ango, E., Limbach, K.L., and Richie, T.L. (2010) Molecular vaccines for malaria. Hum. Vaccin., 6, 54-77.
47. Trier, N.H., Hansen, P.R., and Houen, G. (2012) Production and characterization of peptide antibodies. Methods, 56, 136-144.
48. Sangdee, K., Thummabenjapone, P., and Sangdee, A. (2012) Evaluation of antigen preparation methods for polyclonal antibody production against Streptomyces spp. Br. Microbiol. Res. J., 2, 137-145.
49. Hermanson, G.T. (1996) Bioconjugate Techniques, Academic Press, San Diego, CA.
50. Hanly, W.C., Artwohl, J.E., and Bennett, B.T. (1995) Review of polyclonal antibody production procedures in mammals and poultry. ILAR J., 37, 93.
51. Abolade, A.S. and Ahmadu, R.O. (2012) Plants as animals alternatives in the production of antibodies and other therapeutic agents. Asian J. Pharm. Biol. Res., 2, 1-11.
52. Hua, J. and Hendriksen, C. (2010) Immunization for production of antibodies, in Handbook of Laboratory Animal Science, Essential Principals and Practices, 3rd edn, vol. I, Chapter 16 (eds J. Hau and S.J. Schapiro), CRC Press, Boca Raton, FL.
53. Cox, J.C. and Coulter, A.R. (1997) Adjuvants - a classification and review of their modes of action. Vaccine, 15, 248-256.
54. Reed, S.G., Bertholet, S., Coler, R.N., and Friede, M. (2009) New horizons in adjuvants for vaccine development. Trends Immunol., 30, 23-32.
55. Swain, J.L., Sroller, V., Wong, C., Zhang, S., Halvorson, S.J., Herron, A.J., Kozinetz, C.A., and Butel, J.S. (2012) Effects of route of inoculation and viral genetic variation on antibody responses to polyomavirus SV40 in Syrian golden hamsters. Comp. Med., 62, 400-408.
56. Foote, J.B., Mahmoud, T.I., Vale, A.M., and Kearny, J.F. (2012) Cellular immunology and immune regulation: long-term maintenance of polysaccharide-specific antibodies by IgM-secreting cells. J. Immunol., 188, 57-67.
57. Codices, V., Martins, C., Novo, C., de Sousa, B., Lopes, A., Borrego, M., and Matos, O. (2013) Dynamics of cytokines and immunoglobulins serum profiles in primary and secondary Cryptosporidium parvum infection: usefulness of Luminex® xMAP technology. Exp. Parasitol., 133, 106-113.
58. Wongchuphana, R., Teyb, B.T., Tan, W.S., Subramanianc, S.K., Taipa, F.S., and Linga, T.C. (2011) Purification of rabbit polyclonal immunoglobulin G using anion exchangers. Process Biochem., 46, 101-107.
59. Grodzki, A.C. and Berenstein, E. (2010) Introduction to the purification of antibodies, in Immunocytochemical Methods and Protocols, Methods in Molecular Biology, vol. 588, Chapter 2 (eds C. Oliver and M.C. Jamur), Humana Press, a part of Springer Science.
60. Agaton, C., Falk, R., Guthenberg, I.H., Göstring, L., Uhlén, M., and Hober, G. (2004) Selective enrichment of monospecific polyclonal antibodies for antibody-based proteomics efforts. J. Chromatogr. A, 1043, 33-40.
61. Newcombe, C. and Newcombe, A.R. (2007) Antibody production: polyclonalderived biotherapeutics. J. Chromatogr. B, 848, 2-7.
62. Casadevall, A. (1999) Passive antibody therapies: progress and continuing challnge. Clin. Immunol., 93, 5-15.
63. Weant, K.A., Johnson, P.N., Bowers, R.C., and Armitstead, J.A. (2010) Evidence-based, multidisciplinary approach to the development of a crotalidae polyvalent antivenin (CroFab) protocol at a university hospital. Ann. Pharmacother., 44, 447-455.
64. Schaeffer, T.H., Mlynarchek, S.L., Stanford, C.F., Delgado, J., Holstege, C.P., Olsen, D., and Bogdan, G.M. (2010) Treatment of chronically digoxinpoisoned patients with a newer digoxin immune fab-a retrospective study. J. Am. Osteopath Assoc., 110, 587-592.
65. ElBakri, A., Nelson, P.N., and Odeh, R.O.A. (2010) The state of antibody therapy. Hum. Immunol., 71, 189-196.
66. Boels, D., Hamel, J.F., Deguigne, M.B., and Harry, P. (2012) European viper envenomings: assessment of Viperfav and other symptomatic treatments. Clin. Toxicol., 50, 189-196.
67. Gaber, A.O., Monaco, A.P., Russell, J.A., Lebranchu, Y., and Mohty, M. (2010) Rabbit antithymocyte globulin (Thymoglobulin): 25 years and new frontiers in solid organ transplantation and haematology. Drugs, 70, 691-732.
68. Groothuis, J.R., Hoopes, J.M., and Jessie, V.G.H. (2011) Prevention of serious respiratory syncytial virus-related illness. I: disease pathogenesis and early attempts at prevention. Adv. Ther., 28 (2), 91-109.
69. Stravitz, R.T., Shiffman, M.L., Kimmel, M., Puri, P., Luketic, V.A., Sterling, R.K., Sanyal, A.J., Cotterell, A.H., Posner, M.P., and Fisher, R.A. (2012) Substitution of tenofovir/emtricitabine for Hepatitis B immune globulin prevents recurrence of Hepatitis B after liver transplantation. Liver Int., 32, 1138-1145.
70. Beck, A., Wurch, T., Bailly, C., and Corvaia, N. (2010) Strategies and challenges for the next generation of therapeutic antibodies. Nat. Rev. Immunol., 10, 345-352.
71. Meijer, P.J., Andersen, P.S., Hansen, M.H., Steinaa, L., Jensen, J., Lantto, J., Oleksiewicz, M.B., Tengbjerg, K., Poulsen, T.R., Coljee, V.W., Bregenholt, S., Haurum, J.S., and Nielsen, L.S. (2006) Isolation of human antibody repertoires with preservation of the natural heavy and light chain pairing. J. Mol. Biol., 358, 764-772.
72. Meijer, P.J., Nielsen, L.S., Lantto, J., and Jensen, A. (2009) Human antibody repertoires. Ther. Antibodies - Meth. Mol. Biol., 525, 261-277.
73. Wiberg, F.C., Rasmussen, S.K., Frandsen, T.P., Rasmussen, L.K., Tengbjerg, K., Coljee, V.W., Sharon, J., Yang, C.-Y., Bregenholt, S., Nielson, L.S., Haurum, J.S., and Tolstrup, A.B. (2006) Production of target-specific recombinant human polyclonal antibodies in mammalian cells. Biotechnol. Bioeng., 94, 396-405.
74. Bregenholt, S., Jensen, A., Lantto, J., Hyldig, S., and Haurum, J.S. (2006) Recombinant human polyclonal antibodies:a new class of therapeutic antibodies against viral infections. Curr. Pharm. Des., 12, 2007-2015.